Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Net Cash Flow (2016 - 2025)

Lipocine's Net Cash Flow history spans 13 years, with the latest figure at -$2.1 million for Q3 2025.

  • For Q3 2025, Net Cash Flow fell 18.37% year-over-year to -$2.1 million; the TTM value through Sep 2025 reached $82481.0, up 125.01%, while the annual FY2024 figure was $1.4 million, 11.65% down from the prior year.
  • Net Cash Flow reached -$2.1 million in Q3 2025 per LPCN's latest filing, down from $2.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $2.8 million in Q1 2022 to a low of -$8.6 million in Q1 2021.
  • Average Net Cash Flow over 5 years is -$1.1 million, with a median of -$941989.0 recorded in 2023.
  • Peak YoY movement for Net Cash Flow: tumbled 617.03% in 2021, then soared 906.88% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$1.6 million in 2021, then surged by 147.97% to $751536.0 in 2022, then dropped by 6.98% to $699052.0 in 2023, then soared by 252.33% to $2.5 million in 2024, then plummeted by 187.01% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Net Cash Flow are -$2.1 million (Q3 2025), $2.6 million (Q2 2025), and -$2.9 million (Q1 2025).